Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 1:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024
iCAD (NASDAQ Cons)
Závěr k 28.3.2024 Změna (%) Změna (USD) Objem obchodů (ks)
1,61 0,63 0,01 74 066
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostiiCAD Inc
TickerICAD
Kmenové akcie:Ordinary Shares
RICICAD.O
ISIN-
Prioritní akcieConv. Pref. Shrs
Poslední známé roční výsledky31.12.2022
Poslední známé čtvrtletní výsledky30.09.2023
Počet zaměstnanců k 31.12.2022 109
Akcie v oběhu k 31.12.2023 26 354 199
MěnaUSD
Kontaktní informace
Ulice98 Spit Brook Rd Ste 100
MěstoNASHUA
PSČ03062-5737
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 038 825 200
Fax16038803843

Business Summary: iCAD, Inc. is a global medical technology company, which provides cancer detection and therapy solutions. The Company is focused on providing breast cancer detection solutions built on artificial intelligence (AI) that empowers radiologists to find cancers. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and a range of high-performance, AI and computer-aided detection (CAD) systems and workflow solutions for 2D and 3D mammography, magnetic resonance imaging and computed tomography (CT). The Company’s Breast AI Suite offers a triple threat of clinically proven cancer detection, density assessment, and risk evaluation solutions, designed to accelerate discovery and improve outcomes. It also offers ProFound AI, a digital breast tomosynthesis (DBT) cancer detection and workflow solution.
Financial Summary: BRIEF: For the nine months ended 30 September 2023, iCAD Inc revenues decreased 17% to $12.6M. Net loss before extraordinary items decreased 15% to $6.5M. Revenues reflect Detection segment decrease of 21% to $4.2M, Therapy segment decrease of 27% to $1.7M, Products segment decrease of 13% to $2.2M. Lower net loss reflects Therapy segment income totaling $593K vs. loss of $797K.
Odvětvová klasifikace
TRBC2009Advanced Medical Equipment
TRBC2012Advanced Medical Equipment & Technology (NEC)
RBSS2004Advanced Medical Equipment
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSIrradiation Apparatus Manufacturing
NAICS2007Electromedical Apparatus Mfg
NAICS2007Irradiation Apparatus Mfg
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
NAICS1997Irradiation Apparatus Manufacturing
SICSurgical And Medical Instruments
SICElectromedical Equipment
SICX-Ray Apparatus And Tubes



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the Board, President, Chief Executive OfficerDana Brown5810.03.202306.01.2023
Chief Financial OfficerEric Lonnqvist-17.04.202317.04.2023
Chief Operating OfficerMichelle Strong-01.05.202301.05.2023
Chief Technology OfficerJonathan Go6015.01.201924.10.2006
Chief Product OfficerVasu Avadhanula-01.05.202301.05.2023